Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9UI32
UPID:
GLSL_HUMAN
Alternative names:
L-glutaminase; L-glutamine amidohydrolase
Alternative UPACC:
Q9UI32; B7Z8Q9; Q8IX91; Q9NYY2; Q9UI31
Background:
Glutaminase liver isoform, mitochondrial, also known as L-glutaminase and L-glutamine amidohydrolase, is pivotal in glutamine catabolism. It catalyzes the synthesis of glutamate and alpha-ketoglutarate, enhancing mitochondrial respiration and ATP production. This enzyme also boosts cellular antioxidant capabilities through NADH and glutathione.
Therapeutic significance:
Understanding the role of Glutaminase liver isoform, mitochondrial could open doors to potential therapeutic strategies.